DRUG-FREE TARGETED TUMOR KILLING WITH MULTIMERIC ANTIBODY CONJUGATE

Monoclonal antibodies show limited clinical efficacy as a single agent therapy for solid and blood cancers. The requisite high doses result in undesired adverse immunogenicity and toxicity. Conjugating antibodies to cytotoxic drug shows durable clinical response. However, antibody drug conjugate designing is complex, with knowledge of linkers, drug and antibody combinations in the context of a specific cancer.

University of Utah researchers are developing a new approach for modifying and improving antibody avidity by using graphene oxide (GO) as a targeted delivery scaffold. The GO-based aqueous composition allows non-covalent association of multiple antibody molecules on individual GO molecules, resulting in high efficacy antibodies.